Global Amyotrophic Lateral Sclerosis Market 2014-2018

Global Amyotrophic Lateral Sclerosis Market 2014-2018

Category : Pharmaceuticals
Published On : January  2014
Pages : 46



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. 
TechNavio's report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp.
Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc.
Key questions answered in this report: 
What will the market size be in 2016/2018 and what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.

 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Rate of Incidence and Prevalence

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape


16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Other Prominent Vendors

16.3 Vendor Ranking 2013

17. Late Stage Pipeline Snapshot

18. Key Vendor Analysis


18.1 Covis Pharmaceutical Inc.

18.1.1 Business Overview

18.1.2 Key Information

18.1.3 SWOT Analysis

18.2 Eisai Co. Ltd.

18.2.1 Business Overview

18.2.2 Key Information

18.2.3 SWOT Analysis

18.3 GlaxoSmithKline plc

18.3.1 Business Overview

18.3.2 Business Segmentation

18.3.3 Key Information

18.3.4 SWOT Analysis

18.4 Mitsubishi Tanabe Pharma Corp.

18.4.1 Business Overview

18.4.2 Business Segmentation

18.4.3 Key Information

18.4.4 SWOT Analysis

19. Other Reports in this Series



List of Exhibits



Exhibit 1: Market Research Methodology

Exhibit 2: Global ALS Drugs Market 2013-2018 (US$ million)

Exhibit 3: Global ALS Drugs Market by Geographical Segmentation 2013

Exhibit 4: GlaxoSmithKline plc: Business Segmentation

Exhibit 5: Mitsubishi Tanabe Pharma Corp.: Business Segmentation



Enquiry Before Buy